Mutations with an effect on CD19 protein were identified in less than one-third of CD19-negative relapsed patients with BCP-ALL treated with blinatumomab in contrast to truncating CD19 mutations in 12/12 patients with CD19-negative relapse after CAR T cell therapy [76]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.